KAM
PTLA

Kazazian Asset Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Kazazian Asset Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-13,155
Closed -$350K – 101
2018
Q3 		$350K Sell
13,155
-6,264
-32% -$205K 0.33% 57
2018
Q2 		$733K Buy
19,419
+2,509
+15% +$96K 0.67% 33
2018
Q1 		$552K Buy
16,910
+3,253
+24% +$143K 0.58% 40
2017
Q4 		$665K Buy
13,657
+1,416
+12% +$71.6K 0.68% 35
2017
Q3 		$661K Buy
+12,241
New +$719K 0.81% 30

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Kazazian Asset Management's PTLA Position: Q4 2018 in Review

Kazazian Asset Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2018, closing a stake of 13,155 shares — an estimated $350K sold.

Kazazian Asset Management first reported a position in PTLA in Q3 2017 and held it in 5 quarters. The position peaked at $733K in Q2 2018. 181 funds tracked by Wall St. Rank hold PTLA as of Q4 2018.

  • Kazazian Asset Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Kazazian Asset Management sold 13,155 Portola Pharmaceuticals, Inc. shares in Q4 2018, an estimated $350K.
  • Kazazian Asset Management first reported a position in Portola Pharmaceuticals, Inc. in Q3 2017 and held it in 5 quarters.
  • Kazazian Asset Management's Portola Pharmaceuticals, Inc. position peaked at $733K in Q2 2018.
  • 181 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2018.

Based on Kazazian Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.